BACKGROUND AND PURPOSE: The Woven EndoBridge device proved its effectiveness in the treatment of ruptured and unruptured intracranial aneurysms as a stand-alone device. Before 2016, Woven EndoBridge deployment required at least a 0.021inch microcatheter. In 2016, a smaller device, the Woven EndoBridge 17 with finer size increments that used a 0.017-inch microcatheter, was introduced. We retrospectively analyzed our initial and follow-up results with the Woven EndoBridge 17 in ruptured and unruptured aneurysms. MATERIALS AND METHODS: One hundred twenty-seven intracranial aneurysms in 117 patients were scheduled for treatment with the Woven EndoBridge 17 between June 2017 and February 2019. Twenty-nine aneurysms were ruptured. RESULTS: Treatment was performed as intended in 124 of 127 cases (97.6%). Additional devices such as stents or coils were used in 12 cases (9.7%). Five thromboembolic complications and 1 hemorrhagic complication were encountered, resulting in clinical deterioration in 2 patients. The overall morbidity and mortality in the entire series have been 1.7% and 0.0% to date, respectively. The follow-up results at 3 and 12 months revealed complete occlusion in 76.1% (70/92) and 78.0% (32/41). CONCLUSIONS: The Woven EndoBridge 17 device is safe in the treatment of small broad-based aneurysms without the general need for additional devices. The low complication rate and the promising follow-up results underline the value of this technique in a growing range of endovascular treatment options for intracranial aneurysms. ABBREVIATIONS: AcomA ¼ anterior communicating artery; GCP ¼ good clinical practice T he concept of intra-aneurysmal flow disruption consists of a hemodynamically active implant placed inside the aneurysm sac, which, in combination with an attenuated coverage of the neck area, acts as a scaffold for final neointimal growth, resulting in an intra-aneurysmal thrombosis. Experience with the Woven EndoBridge device (WEB; Sequent Medical, Aliso Viejo, California) as the most established flow disruptor is growing, and its safety and effectiveness in the treatment of ruptured and unruptured aneurysms have been documented in numerous publications including clinical trials. 1-7 A potential drawback in treatment with the WEB device consisted of comparatively large microcatheters needed for deployment. In the initial phase, a 0.033-or a 0.027-inch microcatheter was necessary for every WEB device, while in 2015, a modification of the device resulted in the possibility of implanting WEB devices via a 0.021-inch microcatheter. The WEB 17 system, which became available in December 2016, is supposed to facilitate the treatment of small broad-based aneurysms. The possibility of using a 0.017-inch microcatheter might enable the operator to catheterize more distally located lesions and to treat more complex and smaller aneurysms with a potentially lower risk of vessel injury compared with larger catheters. The addition of the WEB 17 system to the pre-existing range of WEB devices, therefore, expands the poss...